FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.2566 -0.0834 (-24.53%)

Streaming Delayed Price Updated: 1:48 PM EST, Nov 24, 2025 Add to My Watchlist

Price and Volume

Volume	3,522,391
Open	0.2700
Bid (Size)	0.2560 (500)
Ask (Size)	0.2571 (1,200)
Prev. Close	0.3400
Today's Range	0.2400 - 0.2705
52wk Range	0.2802 - 2.980
Shares Outstanding	38,262,586
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Top movers in Monday's session ↗

Today 12:30 EST

Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

The market is filled with gapping stocks in Monday's session. ↗

Today 10:30 EST

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Performance

YTD	-87.1%	-87.1%
1 Month	-41.2%	-41.2%
3 Month	-58.0%	-58.0%
6 Month	-68.4%	-68.4%
1 Year	-91.0%	-91.0%

More News

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Today 9:00 EST

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

November 20, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

November 19, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 19, 2025

Via Benzinga

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

November 19, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 06, 2025

Via Benzinga

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

October 31, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics to Present at Bio-Europe 2025

October 24, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics to Present at the 2025 ThinkEquity Conference

October 14, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

September 26, 2025

Via ACCESS Newswire

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

September 23, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

September 12, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

September 11, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

September 10, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

August 27, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

July 31, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

July 28, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

July 11, 2025

Via ACCESS Newswire

FibroBiologics to Present at the Advanced Wound Care Summit USA

July 11, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

July 09, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

July 07, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

July 03, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is FibroBiologics, Inc. - Common Stock publicly traded?

Yes, FibroBiologics, Inc. - Common Stock is publicly traded.

What exchange does FibroBiologics, Inc. - Common Stock trade on?

FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for FibroBiologics, Inc. - Common Stock?

The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market

What is the current price of FibroBiologics, Inc. - Common Stock?

The current price of FibroBiologics, Inc. - Common Stock is 0.2566

When was FibroBiologics, Inc. - Common Stock last traded?

The last trade of FibroBiologics, Inc. - Common Stock was at 11/24/25 01:48 PM ET

What is the market capitalization of FibroBiologics, Inc. - Common Stock?

The market capitalization of FibroBiologics, Inc. - Common Stock is 9.82M

How many shares of FibroBiologics, Inc. - Common Stock are outstanding?

FibroBiologics, Inc. - Common Stock has 10M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.